Solid Biosciences Welcomes Industry Expert Dr. Martin Freed To Its Board Of Directors
Ilan Ganot, Co-Founder and CEO, Assumes Additional Role of President
Gilad Hayeem, Co-Founder, President and Board Member, Retires to Pursue Other Activities
CAMBRIDGE, Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that Martin Freed, M.D., F.A.C.P., a biopharmaceutical expert with more than 25 years of industry experience, has joined its Board of Directors. Additionally, Gilad Hayeem, Solid’s Co-Founder, Director and President, has retired from his role as President and from Solid’s Board to pursue other activities. Ilan Ganot, Co-Founder and Chief Executive Officer, has now also assumed the role of President.
“I want to thank Gilad for his many significant contributions to Solid and service to the Duchenne muscular dystrophy community,” said Andrey Zarur, Ph.D., Co-Founder and Chairman of the Board of Solid Biosciences. “As a member of our founding team, he played an instrumental role in the creation and strategic direction of the company. While I am saddened by his departure, I am excited to continue to collaborate with him as a thought leader as we jointly address this horrific disease. We wish him the best of luck in his future endeavors.”
Dr. Zarur continued, “Dr. Freed’s breadth of hands-on experience in helping companies advance innovative products through clinical development and approval is impressive. He brings this expertise to Solid, and we are delighted to welcome him to our Board.”
“Gilad was the first to support our vision that we can and should aggressively pursue a plan to bring meaningful therapies to all patients with Duchenne muscular dystrophy,” said Ilan Ganot, Co-Founder and Chief Executive Officer of Solid Biosciences. “His compassion, dedication and hands-on involvement helped make Solid what it is today.”
Dr. Martin Freed brings to Solid more than 25 years of strategic development and operational expertise from across the biopharmaceutical and life sciences industries. As a seasoned drug development executive and life sciences entrepreneur, his experience spans from Phase 1 drug development through to post-registration clinical development and medical affairs programming across numerous therapeutic areas.
Dr. Freed has held senior leadership positions with various biopharmaceutical companies, most recently as Co-Founder and Chief Medical Officer of Civitas Therapeutics, Inc., which was acquired by Acorda Therapeutics Inc. in 2014. Prior to Civitas, he held leadership positions at Adnexus Therapeutics, Inc., Vitae Pharmaceuticals, Inc. and SmithKline Beecham Pharmaceuticals/GlaxoSmithKline. Dr. Freed has been published in more than 40 peer reviewed manuscripts, four book chapters and more than 90 abstracts related to an array of drug development and translational medicine programs. Currently, Dr. Freed also holds Board positions with Dicerna Pharmaceuticals, Inc. and Sojournix, Inc.
Dr. Freed performed his internal medicine residency at Temple University Hospital and nephrology fellowship at Yale-New Haven Hospital.
About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Currently, Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. For more information, please visit www.solidbio.com.
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with Solid’s ability to obtain and maintain necessary approvals from the FDA and other regulatory authorities and investigational review boards at clinical trial sites; enroll patients in its clinical trials; continue to advance SGT-001 in clinical development; replicate in later clinical trials positive results found in preclinical studies and earlier stages of clinical development; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its product candidates; compete successfully with other companies that are seeking to develop DMD treatments and gene therapies; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
Contact:
Solid Biosciences
Kate Niazi-Sai
+1 617-337-4680
media@solidbio.com
investors@solidbio.com
© 2018 GlobeNewswire, Inc. All Rights Reserved.
Tesla (Nasdaq: TSLA) Announces Date for First Quarter 2021 Financial Results and Webcast
